Craig Kevin James sold $192K of ATAI
Craig Kevin James (Chief Medical Officer) sold 42,579 shares of AtaiBeckley Inc. (ATAI) at $4.51 ($0.19M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a disclosed, pre-arranged insider transaction; it is more relevant for monitoring insider activity than for forecasting fundamentals.
Market read
Traders may note the insider sale for sentiment/positioning, but the 10b5-1 framing limits actionable inference.
What to watch
The filing does not indicate whether other insiders or the company made offsetting purchases, nor does it provide any operational/clinical update.
Background
The article is an SEC Form 4 insider transaction disclosure for AtaiBeckley Inc.
Ticker impact
SEC Form 4 shows CMO Craig Kevin James sold 42,579 shares of AtaiBeckley at $4.51 on 2026-06-25 under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted given pre-arranged 10b5-1 structure.
The filing is a disclosed insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerAtaiBeckley Inc.
Company whose CMO filed an SEC Form 4 insider sale disclosure.
- insiderCraig Kevin James
Chief Medical Officer who sold shares under a 10b5-1 plan.
